+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cyramza (ramucirumab; Eli Lilly) Drug Overview 2019

  • ID: 4462148
  • Drug Pipelines
  • September 2019
  • Region: Global
  • 65 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Cyramza (ramucirumab; Eli Lilly) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain of VEGFR-2 found on tumor vasculature. The VEGF protein is an essential component of the angiogenesis pathway, which is critical for blood vessel formation, tumor growth, invasion, and metastasis.

Cyramza inhibits tumor angiogenesis by preventing VEGF ligands VEGF-A, VEGF-C, and VEGF-D from binding to and activating the VEGFR-2 receptor, which in turn prevents the proliferation and migration of endothelial cells necessary for angiogenesis to occur. The lack of new blood vessels starves the tumors of their nutrient supply, resulting in tumor growth inhibition.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
  • Drug Overview
  • Product Profiles
  • Cyramza : Hepatocellular carcinoma (HCC)
  • Cyramza : Non-small cell lung cancer (NSCLC)
  • Cyramza : Gastric cancer
  • Cyramza : Colorectal cancer (CRC)
  • Cyramza : Bladder cancer
LIST OF FIGURES
Figure 1: The author's drug assessment summary of Cyramza for HCC
Figure 2: The author's drug assessment summary of Cyramza for HCC
Figure 3: Cyramza sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
Figure 4: Cyramza for non-small cell lung cancer – SWOT analysis
Figure 5: The author's drug assessment summary for Cyramza in non-small cell lung cancer
Figure 6: The author's drug assessment summary for Cyramza in non-small cell lung cancer
Figure 7: Cyramza sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 8: Cyramza for gastric cancer – SWOT analysis
Figure 9: The author's drug assessment summary of Cyramza for gastric cancer
Figure 10: The author's drug assessment summary of Cyramza for gastric cancer
Figure 11: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
Figure 12: Cyramza for colorectal cancer – SWOT analysis
Figure 13: The author's drug assessment summary of Cyramza for colorectal cancer
Figure 14: The author's drug assessment summary of Cyramza for colorectal cancer
Figure 15: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 16: Cyramza for urothelial bladder cancer – SWOT analysis
Figure 17: The author's drug assessment summary for Cyramza in urothelial bladder cancer
Figure 18: The author's drug assessment summary for Cyramza in urothelial bladder cancer

LIST OF TABLE
Table 1: Recent high-impact events for Cyramza in HCC
Table 2: Cyramza drug profile
Table 3: Approval history of Cyramza for HCC in the US, Japan, and five major EU markets
Table 4: Trials of Cyramza for HCC
Table 5: Cyramza for HCC – SWOT analysis
Table 6: Cyramza drug profile
Table 7: Cyramza pivotal trial data in non-small cell lung cancer
Table 8: Cyramza ongoing late-phase clinical trials in non-small cell lung cancer
Table 9: Cyramza sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 10: Cyramza patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 11: Cyramza drug profile
Table 12: Cyramza pivotal trial data in gastric cancer
Table 13: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 14: Cyramza patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017–26
Table 15: Cyramza drug profile
Table 16: Cyramza Phase III data in colorectal cancer
Table 17: Cyramza Phase I trials in colorectal cancer
Table 18: Cyramza sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 19: Patients treated with Cyramza across the US, Japan, and five major EU markets, by country, 2016–25
Table 20: Cyramza drug profile
Table 21: Cyramza Phase III trial in urothelial bladder cancer
Table 22: Cyramza early-phase data in urothelial bladder cancer
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll